Welcome to our dedicated page for Imac Hldgs news (Ticker: BACK), a resource for investors and traders seeking the latest updates and insights on Imac Hldgs stock.
About IMAC Holdings Inc. (Symbol: BACK)
IMAC Holdings Inc. is a pioneering healthcare company that specializes in providing non-invasive, value-based medical care for individuals suffering from movement-restricting conditions and musculoskeletal disorders. Through its network of IMAC Regeneration Centers and BackSpace clinics, the company combines traditional medical practices with cutting-edge life science advancements to deliver innovative treatments aimed at improving patient outcomes and reducing healthcare costs.
The company's core mission is to offer patients effective alternatives to invasive surgical procedures such as knee replacements, hip replacements, spinal fusion surgeries, and ligament transplants. By leveraging proprietary techniques and integrative medical approaches, IMAC Holdings addresses a wide range of conditions, including chronic knee pain, back pain, arthritis, joint damage, and muscular tears. Its treatments are designed to enhance mobility, alleviate pain, and improve the quality of life for patients ranging from professional athletes to independent seniors.
Business Model and Revenue Streams
IMAC Holdings operates on a value-based care model, focusing on achieving measurable patient outcomes. Revenue is primarily generated through patient services offered at its clinics, which include a combination of medical and physical procedures tailored to individual needs. The company's proprietary regenerative medicine techniques and non-invasive therapies further differentiate its offerings in a competitive healthcare market.
IMAC's BackSpace clinics, which are strategically located within retail settings, provide chiropractic and spinal care services, making high-quality, non-invasive treatments more accessible to a broader audience. This dual-clinic approach allows the company to cater to diverse patient demographics while maintaining its commitment to cost-effective healthcare solutions.
Industry Context and Competitive Landscape
IMAC Holdings operates within the broader healthcare and regenerative medicine industry, a rapidly evolving sector driven by advancements in medical technology and an increasing demand for non-invasive treatment options. The company faces competition from traditional healthcare providers, orthopedic surgeons, and other regenerative medicine practitioners. However, IMAC differentiates itself through its integrative approach, which combines medical expertise with physical therapy to deliver holistic care.
Additionally, the company's emphasis on reducing healthcare costs aligns with broader industry trends toward value-based care, making it an attractive option for patients seeking effective yet affordable treatments. By focusing on patient education and building trust through successful outcomes, IMAC has established itself as a credible alternative to conventional surgical interventions.
Proprietary Treatments and Patient-Centered Care
IMAC Holdings is known for its proprietary regenerative medicine procedures, which are designed to stimulate the body's natural healing processes. These treatments, which include advanced therapies for joint and soft tissue repair, have been trusted by a diverse patient base, from elite athletes to everyday individuals. The company's commitment to patient-centered care is evident in its personalized treatment plans, which are tailored to address the unique needs of each individual.
By prioritizing non-invasive solutions, IMAC aims to minimize recovery times and enhance the overall patient experience. This approach not only improves clinical outcomes but also fosters long-term patient loyalty and word-of-mouth referrals, which are critical to the company's growth strategy.
Challenges and Opportunities
While IMAC Holdings has carved out a niche in the healthcare sector, it faces challenges such as educating patients about the benefits of non-invasive treatments and navigating regulatory requirements for its proprietary procedures. However, the growing demand for cost-effective, minimally invasive healthcare solutions presents significant opportunities for expansion and innovation.
By continuously refining its treatment methodologies and expanding its clinic network, IMAC is well-positioned to capitalize on these trends and solidify its reputation as a leader in regenerative medicine and value-based care.
Conclusion
IMAC Holdings Inc. represents a forward-thinking approach to healthcare, combining traditional medical practices with innovative regenerative medicine techniques. Through its IMAC Regeneration Centers and BackSpace clinics, the company addresses a critical need for non-invasive, cost-effective treatments for movement-restricting conditions. With its patient-centered care model, proprietary procedures, and commitment to improving healthcare outcomes, IMAC Holdings is poised to make a lasting impact in the healthcare industry.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has announced groundbreaking data showing MHC-II protein expression as a superior predictor of pembrolizumab (Keytruda®) response compared to PD-L1. The findings will be presented at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference.
The study, conducted using I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies, including the commonly used companion diagnostic. Only MHC-II expression demonstrated statistically significant correlation with patient outcomes. Patients with higher MHC-II protein levels showed nearly double the response rate compared to unselected patients.
The I-SPY 2 trial, focusing on high-risk stage II and III breast cancer patients undergoing neoadjuvant treatment, is a multicenter, adaptive platform trial. The research suggests that MHC-II testing could significantly improve care by enabling more precise therapy decisions, particularly in cancer types where no biomarker testing is currently used.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has completed the transfer of PLA code 0249U for its proteomic breast cancer assay, previously owned by Theralink Technologies. The code, listed on the Medicare Clinical Laboratory Fee Schedule with a reimbursement rate of $2,219.13, is covered under Palmetto GBA MolDx's 'Proteomics Testing' article (A59636).
The company's proteomic assay measures functional protein activity in breast tumors, offering oncologists data on potential patient responses to targeted therapies. The test is conducted in Ignite's CLIA-certified, CAP-accredited, and NY State-approved laboratory. This acquisition integrates both laboratory capabilities and intellectual property rights, positioning Ignite Proteomics to advance in precision oncology.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has published a significant study in the British Journal of Cancer demonstrating the superiority of protein activation analysis in predicting breast cancer therapy response. The research reveals that direct assessment of protein activation provides better prediction of therapeutic outcomes compared to genomic profiling alone.
The study found that patients with functional activation of the AKT-mTOR signaling axis showed worse response to standard first-line treatment with CDK4/6 inhibitors. Importantly, genomic mutations in PIK3CA, PTEN, or AKT genes showed no correlation with protein activation status or patient outcomes.
The company's Reverse Phase Protein Array (RPPA)-based proteomic assay measures protein activation within the AKT-mTOR pathway, offering the only commercially available and clinically validated test that measures both expression and activation levels of drug targets in breast tumors. This approach enables more precise identification of patients likely to benefit from specific targeted therapies.
IMAC Holdings (NASDAQ: BACK) has launched Ignite Proteomics , a subsidiary focused on protein-based cancer treatment selection. The new venture aims to disrupt the multi-billion-dollar genomic testing market, with an immediate addressable market of $600M in its current clinically approved indication.
Unlike traditional genomic testing, Ignite's multi-protein test provides real-time insights into tumor behavior and drug response, particularly for antibody-drug conjugates (ADCs) and immunotherapies. The platform features novel biomarkers protected by licensed patents, offering physicians enhanced capabilities to select effective treatments and avoid trial-and-error approaches.
The company is actively collaborating with leading cancer centers to expand clinical evidence and integrate its test into routine care. The platform is particularly focused on breast cancer treatment guidelines and aims to provide more accurate insights than traditional gene-based testing methods.
IMAC Holdings (NASDAQ: BACK) has received a deficiency notification from Nasdaq due to its failure to timely file its Q3 2024 Form 10-Q. The company now has until January 21, 2024, to submit a compliance plan. If Nasdaq accepts the plan, IMAC may receive up to 180 calendar days (until May 19, 2025) to regain compliance. While the notice has no immediate effect on IMAC's stock listing, failure to regain compliance could result in delisting from Nasdaq Capital Market. The company intends to submit a compliance plan within the 60-day period but cannot guarantee success in maintaining its listing.
IMAC Holdings (NASDAQ: BACK) has received an extension from Nasdaq until February 17, 2025 to regain compliance with Listing Rule 5250(c)(1) by filing its Q2 2024 Form 10-Q. The delay in filing is attributed to three main factors: the acquisition of assets from Theralink Technologies, the exchange of Convertible Preferred Stocks and warrants, and staffing challenges including the temporary loss of a key financial staff member. The extension does not immediately affect the company's listing or trading status on the Nasdaq Capital Market.
IMAC Holdings Inc. (Nasdaq: BACK) has launched a new subsidiary, Ignite Proteomics , introducing a groundbreaking precision oncology assay for breast cancer treatment using Reverse Phase Protein Array (RPPA) technology. This follows IMAC's acquisition of key assets from Theralink Technologies, Inc. A landmark clinical case study published in npj Precision Oncology demonstrates the power of RPPA in precision oncology.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
IMAC Holdings (NASDAQ: BACK) has received a deficiency notification from Nasdaq due to the delayed filing of its Q2 2024 Form 10-Q. This non-compliance with Nasdaq Listing Rule 5250(c)(1) does not immediately affect the company's listing on the Nasdaq Capital Market. IMAC has until October 20, 2024, to submit a compliance plan and could potentially receive an extension until February 17, 2025, to regain compliance if Nasdaq accepts the plan. The company is working to file the Form 10-Q and take necessary steps to maintain its Nasdaq listing. However, there is no guarantee of success, and IMAC could face delisting if it fails to meet the requirements within the given timeframe.
IMAC Holdings has appointed Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move aims to advance IMAC’s position in proteomics and precision medicine. Dr. Schwartz, with over 18 years of experience in radiotherapy and precision oncology, and Dr. Beitsch, with a background in surgical oncology and genomics, will contribute their expertise to guide IMAC's strategic initiatives. Their appointments align with the company's mission to revolutionize cancer treatment through proteomic technologies.
IMAC Holdings announced a major leadership transition, appointing Faith Zaslavsky as CEO, succeeding Jeff Ervin. This move aims to drive forward its newly acquired assets in the proteomics and precision medicine industry.
Zaslavsky brings 23 years of experience in the genomic space, having previously served as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics. Her leadership is expected to enhance IMAC's mission of providing personalized treatment plans for cancer patients.
IMAC's RPPA technology, proven through clinical trials as a superior indicator for drug selection in breast cancer, is set to become an essential test for various cancers. The board now consists of three independent members following the resignation of co-founders Dr. Matt Wallis and Jeff Ervin, with Ervin continuing as a transition consultant.
FAQ
What is the current stock price of Imac Hldgs (BACK)?
What is the market cap of Imac Hldgs (BACK)?
What does IMAC Holdings Inc. do?
How does IMAC Holdings generate revenue?
What makes IMAC Holdings unique in the healthcare industry?
What conditions does IMAC Holdings treat?
Who are IMAC Holdings' target patients?
What is the role of BackSpace clinics within IMAC Holdings?
What challenges does IMAC Holdings face?
What opportunities exist for IMAC Holdings in the healthcare market?
